home / stock / cgtx / cgtx message board
Subject | By | Source | When |
---|---|---|---|
Great! I believe we'll do quite | crudeoil24 | investorshub | 02/22/2023 2:15:32 PM |
Already been here for a few weeks lol. | tw0122 | investorshub | 02/22/2023 1:35:11 PM |
Nice "pop" on FDA phase II news! If | crudeoil24 | investorshub | 02/22/2023 1:18:23 PM |
The START study is supported by a grant | tw0122 | investorshub | 02/22/2023 1:16:02 PM |
Chart is looking better all of the time. | anderson800 | investorshub | 01/06/2023 12:29:11 PM |
$CGTX Love the chart..looking for continuation next week.. | TommyBoyTrader9460 | investorshub | 11/26/2022 2:06:35 PM |
Hopefully this has seen its low and now | anderson800 | investorshub | 11/17/2022 4:25:40 PM |
Nope but not any major loss. | turning stone | investorshub | 08/14/2022 9:44:24 PM |
Were you able to get-out with a profit today? | Pedro2004 | investorshub | 08/04/2022 7:42:44 PM |
While the stock is dropping on no relative | turning stone | investorshub | 04/13/2022 10:33:40 PM |
As a new investor in $CGTX I look | turning stone | investorshub | 04/05/2022 6:42:15 PM |
Hope there is very little shorting done to | turning stone | investorshub | 04/04/2022 11:18:54 PM |
Hopefully we have a winner by end of | turning stone | investorshub | 04/04/2022 11:17:22 PM |
I hope in the Mid 3's is a | turning stone | investorshub | 04/04/2022 11:16:00 PM |
As a new shareholder I fit the need | turning stone | investorshub | 04/04/2022 11:14:14 PM |
In a report released today, Mayank Mamtani from | crudeoil24 | investorshub | 04/04/2022 7:22:00 PM |
Welcome to Cognition Therapeutics Inc ($CGTX). | FooBarAndGrill | investorshub | 01/02/2022 4:40:33 PM |
News, Short Squeeze, Breakout and More Instantly...
Cognition Therapeutics Inc. Company Name:
CGTX Stock Symbol:
NASDAQ Market:
Cognition Therapeutics Inc. Website:
PURCHASE, N.Y., July 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders will host an investor webcast on Monday, July 29, 2024...
PURCHASE, N.Y., July 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, today announced that abstracts summarizing clinical e...
Completed enrollment for Phase 2 SEQUEL trial in mild-to-moderate Alzheimer’s disease (AD); topline results expected 2Q 2023 SHINE (AD) trial currently enrolling patients with first patient in Spain enrolled. Expect full enrollment by end of 2023 Received FDA clearance to...